GlassScriptPhysician profile
Laura V Bowser
NPI 1467471706
$1,725.92
in general payments reported to CMS, 2019-2025
29 companies · $311 in 2025
The $311 reported for 2025 was more than what 85% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $136 · 2021: $101 · 2022: $237 · 2023: $334 · 2024: $265 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $405.73 | 2022-2025 | Azstarys |
| Allergan, INC. | $124.80 | 2019 | |
| Merck Sharp & Dohme LLC | $113.84 | 2019-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Glaxosmithkline, LLC. | $112.59 | 2019-2025 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $94.88 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $86.47 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $85.08 | 2019-2025 | |
| Neos Therapeutics, LP | $77.03 | 2020-2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $75.74 | 2019-2022 | |
| Cranial Technologies, INC | $63.63 | 2020-2025 | Doc Band |
| Xeris Pharmaceuticals, INC. | $56.56 | 2024-2025 | Gvoke Hypopen |
| Shire North American Group INC | $45.16 | 2019 | |
| Abbott Laboratories | $41.26 | 2022-2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $35.87 | 2023-2025 | Qelbree, Qelbree |
| Astellas Pharma US INC | $34.72 | 2025 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $30.72 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $30.63 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $27.29 | 2019 | |
| Ibsa Pharma INC. | $27.18 | 2020 | |
| Janssen Pharmaceuticals, INC | $24.59 | 2020 | |
| Sobi, INC | $18.40 | 2019 | |
| Novo Nordisk INC | $16.72 | 2025 | Ozempic |
| Sanofi-Aventis U.S. LLC | $15.25 | 2023 | |
| Vertical Pharmaceuticals, LLC | $14.15 | 2025 | Relexxii |
| Amarin Pharma, INC. | $14.00 | 2021 | |
| Noven Therapeutics, LLC | $13.97 | 2023 | Xelstrym |
| Abbvie INC. | $13.72 | 2020 | |
| Aimmune Therapeutics, INC. | $13.56 | 2025 | Vowst |
| Mylan Pharmaceuticals INC. | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Bowser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.